HIF1A and colorectal carcinoma: Interestingly, in clinical practice, these results propose evidence that HIF-1α and the products generated by HIF-1α-regulated metabolic processes could be employed as a metabolic signature in the diagnosis, prognosis, and treatment of HCC, HNSC, and non-invasive CRC, as it has been described in other types of cancer [108,109,110,111].